A preliminary study of microRNA expression in different types of primary melanoma.
Journal
Bosnian journal of basic medical sciences
ISSN: 1840-4812
Titre abrégé: Bosn J Basic Med Sci
Pays: Bosnia and Herzegovina
ID NLM: 101200947
Informations de publication
Date de publication:
01 May 2020
01 May 2020
Historique:
received:
05
05
2019
accepted:
28
07
2019
pubmed:
4
9
2019
medline:
20
3
2021
entrez:
4
9
2019
Statut:
epublish
Résumé
MicroRNAs (miRNAs) have been proven to regulate the development and progression of cancer through various mechanisms. The aim of the present study was to compare miRNA expression between primary melanomas from different sites. We analyzed the expression of 84 miRNAs in 27 primary melanoma and 5 nevus formalin-fixed paraffin-embedded (FFPE) samples using the Human Cancer PathwayFinder miScript miRNA PCR Array. The FFPE samples were obtained from the archives of the Municipal Clinical Emergency Hospital of Timisoara and included 10 cutaneous melanomas, 10 uveal melanomas, 7 mucosal melanomas, and 5 cutaneous nevi. Out of 84 miRNAs, 11 miRNAs showed altered expression in all types of melanoma compared with the nevi. Among these, miR-155-5p, miR-9-5p, miR-142-5p, miR-19a-3p, miR-134-5p, and miR-301a-3p were upregulated, while miR-205-5p, miR-203a-3p, miR-27b-3p, miR-218-5p, and miR-23b-3p were downregulated. The highest similarity in miRNA expression pattern was found between uveal and mucosal melanoma groups, i.e., 15 miRNAs had altered expression in both groups. Overall, we identified several miRNAs with significantly altered expression in primary melanomas, including those reported for the first time in this type of cancer. Among them, mir-9-5p, mir-203a-3p, mir-19a-3p, mir-27b-3p, and mir-218-5p showed altered expression in all three melanoma types vs. nevi. Further research should explore the potential of these miRNAs in melanoma.
Identifiants
pubmed: 31479413
doi: 10.17305/bjbms.2019.4271
pmc: PMC7202197
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-208Références
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
pubmed: 18980976
Clin Cancer Res. 2010 Mar 1;16(5):1577-86
pubmed: 20179230
Microrna. 2018;7(3):156-166
pubmed: 29962353
J Invest Dermatol. 2016 Jan;136(1):245-254
pubmed: 26763444
Cancer Lett. 2017 Sep 10;403:175-185
pubmed: 28634044
Basic Clin Pharmacol Toxicol. 2018 Dec;123(6):670-677
pubmed: 29924913
PLoS One. 2013 Dec 16;8(12):e82471
pubmed: 24358187
Am J Pathol. 2003 Nov;163(5):1765-70
pubmed: 14578177
Mod Pathol. 2014 Oct;27(10):1386-93
pubmed: 24603591
Ann Otol Rhinol Laryngol. 1974 Jul-Aug;83(4):515-9
pubmed: 4137290
Cancer. 1988 Apr 1;61(7):1364-70
pubmed: 3345491
Br J Cancer. 2012 Jan 31;106(3):553-61
pubmed: 22223089
An Bras Dermatol. 2018 Jun;93(3):373-376
pubmed: 29924223
Cell Death Dis. 2018 Feb 7;9(2):188
pubmed: 29416005
Acta Pathol Jpn. 1987 Jul;37(7):1105-14
pubmed: 3661192
Laryngoscope. 1972 May;82(5):824-35
pubmed: 4554758
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Int J Oncol. 2009 Aug;35(2):393-400
pubmed: 19578755
Pathol Res Pract. 2018 Dec;214(12):2039-2045
pubmed: 30322806
Virchows Arch A Pathol Anat Histopathol. 1991;418(4):327-31
pubmed: 2024454
J Cell Mol Med. 2009 Sep;13(9B):3918-28
pubmed: 19228262
Cell Death Dis. 2017 May 11;8(5):e2770
pubmed: 28492560
J Cell Physiol. 2018 Jul;233(7):5133-5141
pubmed: 29226953
J Biol Chem. 2011 May 13;286(19):16606-14
pubmed: 21454583
Melanoma Res. 2011 Dec;21(6):555-9
pubmed: 21971089
PLoS One. 2013 Sep 04;8(9):e72699
pubmed: 24023765
Cell Physiol Biochem. 2018;46(3):1275-1285
pubmed: 29680837
Eur J Cancer. 2016 Jan;53:25-32
pubmed: 26693896
Cancers (Basel). 2019 Jan 10;11(1):
pubmed: 30634628
Oncol Lett. 2019 May;17(5):4139-4144
pubmed: 30944607
RNA Biol. 2015;12(8):810-23
pubmed: 26176991
Cell Physiol Biochem. 2018;46(6):2215-2231
pubmed: 29734189
Clin Cancer Res. 2013 Jun 15;19(12):3143-52
pubmed: 23633454
Int Rev Immunol. 2009;28(5):264-84
pubmed: 19811312
Mol Biol (Mosk). 2018 Mar-Apr;52(2):220-230
pubmed: 29695690
Cancer. 1963 Jan;16:48-50
pubmed: 14025842
Cancer. 1964 Jul;17:912-3
pubmed: 14179553
J Exp Clin Cancer Res. 2017 Oct 5;36(1):138
pubmed: 28982387
Cancer Manag Res. 2018 May 03;10:989-1003
pubmed: 29760567
Int J Cancer. 2007 Jul 15;121(2):257-64
pubmed: 17372901
PLoS One. 2008 Jul 02;3(7):e2557
pubmed: 18596939
J Pathol. 2013 Jul;230(3):261-9
pubmed: 23620124
FEBS Open Bio. 2017 Jul 10;7(8):1085-1091
pubmed: 28781949
Biomed Pharmacother. 2017 Dec;96:1170-1178
pubmed: 29239816
Arch Oral Biol. 1997 Jan;42(1):77-81
pubmed: 9134118
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(2):105-61
pubmed: 16291526
Biochem Biophys Res Commun. 2017 Sep 16;491(2):374-381
pubmed: 28728844
Oncotarget. 2016 May 10;7(19):28075-85
pubmed: 27057632
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Mol Ther. 2013 Jun;21(6):1204-11
pubmed: 23629002
Mol Cancer. 2012 Jul 02;11:44
pubmed: 22747855
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4205-12
pubmed: 27548891
Cell Tissue Res. 2013 Jan;351(1):85-98
pubmed: 23111773
Med Sci Monit. 2017 Dec 24;23:6089-6098
pubmed: 29275424
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8
pubmed: 19359473
Exp Dermatol. 2009 Sep;18(9):799-819
pubmed: 19659579
Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4113-4123
pubmed: 29028088
Carcinogenesis. 2012 Oct;33(10):1823-32
pubmed: 22693259
PLoS One. 2010 Mar 12;5(3):e9685
pubmed: 20300190
FEBS J. 2009 Oct;276(19):5537-46
pubmed: 19702828